GB2491539A - Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome - Google Patents

Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome Download PDF

Info

Publication number
GB2491539A
GB2491539A GB1218050.1A GB201218050A GB2491539A GB 2491539 A GB2491539 A GB 2491539A GB 201218050 A GB201218050 A GB 201218050A GB 2491539 A GB2491539 A GB 2491539A
Authority
GB
United Kingdom
Prior art keywords
glucose metabolism
birt
hogg
treatment
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1218050.1A
Other versions
GB201218050D0 (en
Inventor
Andrew Tee
Keith Baar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myrovlytis Technology Ventures Ltd
Original Assignee
Myrovlytis Technology Ventures Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myrovlytis Technology Ventures Ltd filed Critical Myrovlytis Technology Ventures Ltd
Publication of GB201218050D0 publication Critical patent/GB201218050D0/en
Publication of GB2491539A publication Critical patent/GB2491539A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A composition comprising an inhibitor of glucose metabolism for use in the treatment of Birt-Hogg-Dubé syndrome. The inhibitor of glucose metabolism may be a glycolytic inhibitor. The inhibitor of glucose metabolism may be an inhibitor of pyruvate metabolism. Suitable inhibitors of glucose metabolism include 2-deoxy-D- glucose or a pharmaceutically acceptable salt or solvate thereof or oxamate or a pharmaceutically acceptable salt or solvate thereof.
GB1218050.1A 2010-03-09 2011-03-08 Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome Withdrawn GB2491539A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1003894A GB2478556A (en) 2010-03-09 2010-03-09 A composition for use in the treatment of Birt-Hogg-Dubô sydrome
PCT/GB2011/050454 WO2011110842A2 (en) 2010-03-09 2011-03-08 Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome

Publications (2)

Publication Number Publication Date
GB201218050D0 GB201218050D0 (en) 2012-11-21
GB2491539A true GB2491539A (en) 2012-12-05

Family

ID=42136701

Family Applications (2)

Application Number Title Priority Date Filing Date
GB1003894A Withdrawn GB2478556A (en) 2010-03-09 2010-03-09 A composition for use in the treatment of Birt-Hogg-Dubô sydrome
GB1218050.1A Withdrawn GB2491539A (en) 2010-03-09 2011-03-08 Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB1003894A Withdrawn GB2478556A (en) 2010-03-09 2010-03-09 A composition for use in the treatment of Birt-Hogg-Dubô sydrome

Country Status (3)

Country Link
EP (1) EP2544678A2 (en)
GB (2) GB2478556A (en)
WO (1) WO2011110842A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220265584A1 (en) * 2019-07-11 2022-08-25 Emory University Combination Therapies for Managing Cancer
US20230321135A1 (en) * 2020-06-08 2023-10-12 Qatar Foundation For Education, Science And Community Development Targeting of lactate dehydrogenase c, methods of preparing same, and methods of using same in combination with anti-cancer treatments

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062604A2 (en) * 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
WO2004064734A2 (en) * 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Combination therapies for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670330B1 (en) * 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
SI2131821T1 (en) * 2007-03-07 2018-11-30 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
CN105030784A (en) * 2008-10-31 2015-11-11 诺华股份有限公司 Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062604A2 (en) * 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
WO2004064734A2 (en) * 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Combination therapies for the treatment of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANNUAL REVIEW OF MEDICINE, Vol. 61, 2010, W. MARSTON LINEHAN ET AL: "Molecular Diagnosis and Therapy of Kidney Cancer", Pages 329-343 *
CANCER GENETICS AND CYTOGENETICS, ELSEVIER SCIENECE PUBLISHING, Vol. 180, 2008, YANG ET AL: "The UOK 257 cell line: a novel model for studies of the human....", Pages 100-109 *
INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, KLUWER ACADEMIC PUBLISHERS, Vol. 24, 2006, JACQUELINE VUKY ET AL: "Phase II trial of imatinib (Gleevec(R)) in patients with metastatic renal cell carcinoma", Pages 85-88 *
ONCOGENE, Vol. 25, 2006, H PELICANO ET AL: "Glycolysis inhibition for anticancer treatment", Pages 4633-4646 *

Also Published As

Publication number Publication date
GB201218050D0 (en) 2012-11-21
WO2011110842A2 (en) 2011-09-15
EP2544678A2 (en) 2013-01-16
GB201003894D0 (en) 2010-04-21
WO2011110842A3 (en) 2012-05-10
GB2478556A (en) 2011-09-14

Similar Documents

Publication Publication Date Title
AU2012214029A8 (en) Rorgammat inhibitors
UA98141C2 (en) Methods of treating with quinaxoline inhibitors of pi3k-alpha
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
HK1139863A1 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
IL210494A (en) Organic compounds as smo inhibitors and pharmaceutical compositions comprising them for use in the treatment of cancer
IL221372A0 (en) 6 -benzylphenyl- 2 - sulfurterahydropyran-3, 4, 5 -triol derivatives as inhibitors of sodium -glucose cotrans porters 1 and 2 for use in diabetic patients
IL223889B (en) Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
EP2558035A4 (en) Systems and methods for tensioning ligaments and other soft tissues
EP2313091A4 (en) Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
IL216383A0 (en) Compositions for continuous administration of dopa decarboxylase inhibitors
IL232515A0 (en) Nadph oxidase 4 inhibitors and pharmaceutical compositions containing the same
MX2010010300A (en) Mtor inhibitor salt forms.
HK1125831A1 (en) Fat accumulation inhibitor for the treatment of metabolic syndrome
WO2008152822A1 (en) Medicinal agent
IL199829A0 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
EP2756764A4 (en) Sweetener composition for preventing and improving obesity, containing glycolysis inhibitor ingredient
MX2013006319A (en) Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer.
TN2012000242A1 (en) Heterocyclic sulfonamide derivatives
WO2012064396A3 (en) Novel ezrin inhibitors and methods of making and using
GB201105050D0 (en) Pharmaceutical agent
MX2013014398A (en) Heterocyclic sulfonamide derivatives.
TR201900438T4 (en) Non-acylated ghrelin fragments for use in the treatment of Prader-willi syndrome.
EP3406242B8 (en) Tlr4 antagonist for use in the treatment of increased ammonia plasma levels
GB2491539A (en) Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome
IL182055A0 (en) Agent for prophylaxis or treatment of metabolic syndrome

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)